Wixela Inhub

Overview

fluticasone propionate

corticosteroid

• CYP3A4 substrate
• immunomodulatory effects
• interferes w/ ACTH analog test

salmeterol inhaled

beta-2 agonist

• CYP3A4 substrate
• hypertensive effects
• hypokalemia
• prolongs QT interval (conditional)
• tachycardia

Contraindicated

• desmopressin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

desmopressin

2 interactions

Contraindicated

fluticasone propionate + desmopressin

DESMOPRESSIN INJECTABLE: contraindicated; OTHER DESMOPRESSIN ROUTES: monitor sodium: combo may incr. risk of hyponatremia, including life-threatening (additive effects)

Monitor/Modify Tx

salmeterol inhaled + desmopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• pimozide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pimozide

1 interaction

Contraindicated

salmeterol inhaled + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• thioridazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

thioridazine

1 interaction

Contraindicated

salmeterol inhaled + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• acebutolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

acebutolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + acebutolol

use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

• adagrasib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

adagrasib

2 interactions

Avoid/Use Alternative

fluticasone propionate + adagrasib

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + adagrasib

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• albuterol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

albuterol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + albuterol

consider alternative if long-term use; otherwise, monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• arformoterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

arformoterol inhaled

1 interaction

Avoid/Use Alternative

salmeterol inhaled + arformoterol inhaled

avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• arsenic trioxide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

salmeterol inhaled + arsenic trioxide

use alternative or monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atazanavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + atazanavir

consider alternative, especially if long-term fluticasone use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + atazanavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• atenolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atenolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + atenolol

use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

• bedaquiline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bedaquiline

1 interaction

Avoid/Use Alternative

salmeterol inhaled + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• betaxolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

betaxolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + betaxolol

use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

• bisoprolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bisoprolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + bisoprolol

use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

• carvedilol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

carvedilol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + carvedilol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• ceritinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ceritinib

2 interactions

Avoid/Use Alternative

fluticasone propionate + ceritinib

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + ceritinib

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• chloramphenicol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

chloramphenicol

2 interactions

Avoid/Use Alternative

fluticasone propionate + chloramphenicol

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + chloramphenicol

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• cisapride
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cisapride

1 interaction

Avoid/Use Alternative

salmeterol inhaled + cisapride

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cladribine oral
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cladribine oral

1 interaction

Avoid/Use Alternative

fluticasone propionate + cladribine oral

use alternative: combo may incr. risk of serious infection (additive effects)

• clarithromycin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clarithromycin

2 interactions

Avoid/Use Alternative

fluticasone propionate + clarithromycin

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + clarithromycin

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• cobicistat
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cobicistat

2 interactions

Avoid/Use Alternative

fluticasone propionate + cobicistat

consider alternative (incl. beclomethasone), especially if long-term corticosteroid use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + cobicistat

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• cocaine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cocaine

1 interaction

Avoid/Use Alternative

salmeterol inhaled + cocaine

use alternative or monitor BP, HR, ECG: combo may incr. risk of severe vasoconstriction, HTN, tachycardia, arrhythmias (additive effects)

• conivaptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

conivaptan

1 interaction

Avoid/Use Alternative

fluticasone propionate + conivaptan

avoid combo during and x7 days after conivaptan tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

• crizotinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

crizotinib

1 interaction

Avoid/Use Alternative

salmeterol inhaled + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• darunavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

darunavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + darunavir

consider alternative (incl. beclomethasone), especially if long-term corticosteroid use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + darunavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• desipramine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

desipramine

1 interaction

Avoid/Use Alternative

salmeterol inhaled + desipramine

consider alternative or monitor ECG, BP, HR during and x2wk after desipramine D/C: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• domperidone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

domperidone

1 interaction

Avoid/Use Alternative

salmeterol inhaled + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronabinol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dronabinol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + dronabinol

avoid combo: combo may incr. risk of HTN, tachycardia (additive effects)

• ephedra
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ephedra

1 interaction

Avoid/Use Alternative

salmeterol inhaled + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• epinephrine inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

epinephrine inhaled

1 interaction

Avoid/Use Alternative

salmeterol inhaled + epinephrine inhaled

avoid combo: combo may incr. risk of HTN (including hypertensive crisis), tachycardia, other cardiovascular adverse effects (additive effects)

• esmolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

esmolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + esmolol

use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

• fexinidazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fexinidazole

1 interaction

Avoid/Use Alternative

salmeterol inhaled + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after salmeterol inhaled D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• formoterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

formoterol inhaled

1 interaction

Avoid/Use Alternative

salmeterol inhaled + formoterol inhaled

avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• fosamprenavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fosamprenavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + fosamprenavir

consider alternative, especially if long-term corticosteroid use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + fosamprenavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• fosfomycin injection
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

salmeterol inhaled + fosfomycin injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• furosemide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

furosemide

1 interaction

Avoid/Use Alternative

salmeterol inhaled + furosemide

use alternative or monitor BP, potassium: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• hydroxychloroquine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

salmeterol inhaled + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

idelalisib

2 interactions

Avoid/Use Alternative

fluticasone propionate + idelalisib

avoid combo: combo may incr. plasma fluticasone exposure, risk of serious infection, systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited, additive effects)

salmeterol inhaled + idelalisib

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• itraconazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

itraconazole

2 interactions

Avoid/Use Alternative

fluticasone propionate + itraconazole

avoid combo during and x2wk after itraconazole tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + itraconazole

avoid combo during and x2wk after itraconazole tx: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• ketoconazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ketoconazole

2 interactions

Avoid/Use Alternative

fluticasone propionate + ketoconazole

avoid combo during and up to 1wk after ketoconazole tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + ketoconazole

avoid combo during and up to 1wk after ketoconazole tx: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• labetalol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

labetalol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + labetalol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• landiolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

landiolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + landiolol

use alternative or monitor HR, BP, asthma sx: combo may decr. efficacy of both drugs (antagonistic effects)

• lefamulin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lefamulin

1 interaction

Avoid/Use Alternative

salmeterol inhaled + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

levoketoconazole

2 interactions

Avoid/Use Alternative

fluticasone propionate + levoketoconazole

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + levoketoconazole

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• lonafarnib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lonafarnib

2 interactions

Avoid/Use Alternative

fluticasone propionate + lonafarnib

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + lonafarnib

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• lopinavir/ritonavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lopinavir/ ritonavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + lopinavir/ ritonavir

consider alternative (incl. beclomethasone), especially if long-term corticosteroid use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + lopinavir/ ritonavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• metoprolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

metoprolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + metoprolol

use alternative or monitor BP, bronchospasm sx: combo may decr. efficacy of both drugs (antagonistic effects)

• midodrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

midodrine

1 interaction

Avoid/Use Alternative

salmeterol inhaled + midodrine

use alternative or monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• mifepristone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mifepristone

2 interactions

Avoid/Use Alternative

fluticasone propionate + mifepristone

avoid combo during and x14 days after daily mifepristone use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + mifepristone

avoid combo w/in 14 days of daily mifepristone use: combo may incr. salmeterol exposure, risk of hypokalemia, QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• mobocertinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mobocertinib

1 interaction

Avoid/Use Alternative

salmeterol inhaled + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nadolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nadolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + nadolol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• natalizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

natalizumab

1 interaction

Avoid/Use Alternative

fluticasone propionate + natalizumab

avoid combo: combo may incr. risk of serious infection (additive effects)

• nebivolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nebivolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + nebivolol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• nefazodone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nefazodone

2 interactions

Avoid/Use Alternative

fluticasone propionate + nefazodone

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + nefazodone

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• nelfinavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nelfinavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + nelfinavir

consider alternative, especially if long-term fluticasone use: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + nelfinavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• olodaterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

olodaterol inhaled

1 interaction

Avoid/Use Alternative

salmeterol inhaled + olodaterol inhaled

avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• phenelzine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenelzine

1 interaction

Avoid/Use Alternative

salmeterol inhaled + phenelzine

consider alternative or monitor BP, HR during and x2wk after phenelzine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• pimecrolimus topical
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pimecrolimus topical

1 interaction

Avoid/Use Alternative

fluticasone propionate + pimecrolimus topical

avoid combo: combo may incr. risk of serious infection (additive effects)

• pindolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pindolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + pindolol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• posaconazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

posaconazole

2 interactions

Avoid/Use Alternative

fluticasone propionate + posaconazole

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + posaconazole

avoid combo: combo may incr. salmeterol exposure, risk of hypokalemia, QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• procarbazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

procarbazine

2 interactions

Avoid/Use Alternative

salmeterol inhaled + procarbazine

use alternative or monitor BP, HR during and x2wk after procarbazine D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

Caution Advised

fluticasone propionate + procarbazine

caution advised: combo may incr. risk of serious infection (additive effects)

• propranolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

propranolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + propranolol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• quizartinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

quizartinib

2 interactions

Avoid/Use Alternative

salmeterol inhaled + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Caution Advised

fluticasone propionate + quizartinib

caution advised: combo may incr. risk of serious infection (additive effects)

• ribociclib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ribociclib

2 interactions

Avoid/Use Alternative

fluticasone propionate + ribociclib

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + ribociclib

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

• ritonavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ritonavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + ritonavir

consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + ritonavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• salmeterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

salmeterol inhaled

1 interaction

Avoid/Use Alternative

salmeterol inhaled + salmeterol inhaled

avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, tx)

• sotalol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sotalol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• timolol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

timolol

1 interaction

Avoid/Use Alternative

salmeterol inhaled + timolol

use alternative or monitor BP, bronchospasm sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

• tipranavir
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tipranavir

2 interactions

Avoid/Use Alternative

fluticasone propionate + tipranavir

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + tipranavir

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• toremifene
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

toremifene

1 interaction

Avoid/Use Alternative

salmeterol inhaled + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tucatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tucatinib

2 interactions

Avoid/Use Alternative

fluticasone propionate + tucatinib

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + tucatinib

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• vandetanib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vandetanib

1 interaction

Avoid/Use Alternative

salmeterol inhaled + vandetanib

use alternative or monitor BP, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

• vilanterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vilanterol inhaled

1 interaction

Avoid/Use Alternative

salmeterol inhaled + vilanterol inhaled

avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• voriconazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

voriconazole

2 interactions

Avoid/Use Alternative

fluticasone propionate + voriconazole

avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression (hepatic metabolism inhibited)

salmeterol inhaled + voriconazole

avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• ziprasidone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ziprasidone

1 interaction

Avoid/Use Alternative

salmeterol inhaled + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• abiraterone acetate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + abiraterone acetate

monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

• acetazolamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

acetazolamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + acetazolamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• albuterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

salmeterol inhaled + albuterol inhaled

monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• aliskiren
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

aliskiren

1 interaction

Monitor/Modify Tx

salmeterol inhaled + aliskiren

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• almotriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

almotriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + almotriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• aloe
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

aloe

1 interaction

Monitor/Modify Tx

salmeterol inhaled + aloe

monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

• amiloride
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amiloride

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amiloride

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• aminophylline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

aminophylline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + aminophylline

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• amiodarone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amiodarone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amiodarone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amitriptyline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amitriptyline

monitor BP, HR during and x2wk after amitriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• amlodipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amlodipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amlodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• amoxapine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amoxapine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amoxapine

monitor BP, HR during and x2wk after amoxapine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• amphetamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amphetamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amphetamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• amphotericin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

amphotericin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + amphotericin

monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

• anagrelide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

anagrelide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + anagrelide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• angiotensin II
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

angiotensin II

1 interaction

Monitor/Modify Tx

salmeterol inhaled + angiotensin II

monitor BP: combo may incr. risk of HTN (additive effects)

• apalutamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

apalutamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + apalutamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

apomorphine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + apomorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprocitentan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

aprocitentan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + aprocitentan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• armodafinil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

armodafinil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + armodafinil

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• artemether/lumefantrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + artemether/ lumefantrine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asciminib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

asciminib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + asciminib

monitor BP: combo may incr. risk of HTN (additive effects)

• asenapine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

asenapine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + asenapine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asparaginase
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

asparaginase

1 interaction

Monitor/Modify Tx

salmeterol inhaled + asparaginase

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• atogepant
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atogepant

1 interaction

Monitor/Modify Tx

salmeterol inhaled + atogepant

monitor BP: combo may incr. risk of HTN (additive effects)

• atomoxetine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atomoxetine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + atomoxetine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• atropine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atropine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + atropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• atropine ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atropine ophthalmic

1 interaction

Monitor/Modify Tx

salmeterol inhaled + atropine ophthalmic

monitor BP: combo may incr. risk of HTN (additive effects)

• axitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

axitinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + axitinib

monitor BP: combo may incr. risk of HTN (additive effects)

• azilsartan medoxomil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + azilsartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• azithromycin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

azithromycin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + azithromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• benazepril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

benazepril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + benazepril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• benzphetamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

benzphetamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + benzphetamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• benztropine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

benztropine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + benztropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• betamethasone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

betamethasone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + betamethasone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + betamethasone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• bevacizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bevacizumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + bevacizumab

monitor BP: combo may incr. risk of HTN (additive effects)

• bismuth subsalicylate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bismuth subsalicylate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + bismuth subsalicylate

monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

• brigatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

brigatinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + brigatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• budesonide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

budesonide

2 interactions

Monitor/Modify Tx

salmeterol inhaled + budesonide

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + budesonide

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• bumetanide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bumetanide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + bumetanide

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• bupropion
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bupropion

1 interaction

Monitor/Modify Tx

salmeterol inhaled + bupropion

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• cabozantinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cabozantinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + cabozantinib

monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

• caffeine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

caffeine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + caffeine

monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects)

• caffeine citrate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + caffeine citrate

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• candesartan cilexetil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + candesartan cilexetil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• cannabis
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cannabis

1 interaction

Monitor/Modify Tx

salmeterol inhaled + cannabis

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• captopril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

captopril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + captopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• carfilzomib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

carfilzomib

2 interactions

Monitor/Modify Tx

fluticasone propionate + carfilzomib

consider antiviral prophylaxis: combo may incr. risk of serious infection (additive effects)

salmeterol inhaled + carfilzomib

monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

• celecoxib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

celecoxib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + celecoxib

monitor BP: combo may incr. risk of HTN (additive effects)

• cetuximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cetuximab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + cetuximab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• chloroquine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

chloroquine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorothiazide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + chlorothiazide

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• chlorthalidone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + chlorthalidone

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• cisplatin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cisplatin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + cisplatin

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + cisplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• citalopram
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

citalopram

1 interaction

Monitor/Modify Tx

salmeterol inhaled + citalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clevidipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clevidipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + clevidipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clofazimine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clofazimine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + clofazimine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clomipramine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clomipramine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + clomipramine

monitor BP, HR during and x2wk after clomipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• clonidine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clonidine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + clonidine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• copanlisib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

copanlisib

2 interactions

Monitor/Modify Tx

salmeterol inhaled + copanlisib

monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

Caution Advised

fluticasone propionate + copanlisib

caution advised: combo may incr. risk of serious infection (additive effects)

• corticotropin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

corticotropin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + corticotropin

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + corticotropin

caution advised: combo may incr. risk of serious infection (additive effects)

• cortisone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cortisone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + cortisone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + cortisone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• cosyntropin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cosyntropin

1 interaction

Monitor/Modify Tx

fluticasone propionate + cosyntropin

hold fluticasone on day of test: combo may interfere with test results (fluticasone may alter plasma cortisol levels)

• cyclosporine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cyclosporine

2 interactions

Monitor/Modify Tx

salmeterol inhaled + cyclosporine

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + cyclosporine

caution advised: combo may incr. risk of serious infection (additive effects)

• danazol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

danazol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + danazol

monitor BP: combo may incr. risk of HTN (additive effects)

• darbepoetin alfa
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

darbepoetin alfa

1 interaction

Monitor/Modify Tx

salmeterol inhaled + darbepoetin alfa

monitor BP: combo may incr. risk of HTN (additive effects)

• decitabine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

decitabine

2 interactions

Monitor/Modify Tx

salmeterol inhaled + decitabine

monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + decitabine

caution advised: combo may incr. risk of serious infection (additive effects)

• deflazacort
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

deflazacort

2 interactions

Monitor/Modify Tx

salmeterol inhaled + deflazacort

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + deflazacort

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• degarelix
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

degarelix

1 interaction

Monitor/Modify Tx

salmeterol inhaled + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

desflurane

1 interaction

Monitor/Modify Tx

salmeterol inhaled + desflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desvenlafaxine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + desvenlafaxine

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• dexamethasone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dexamethasone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + dexamethasone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + dexamethasone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• dexmedetomidine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dexmedetomidine

monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dexmedetomidine injection

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmethylphenidate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dexmethylphenidate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dexmethylphenidate

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• dextroamphetamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dextroamphetamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dextroamphetamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• dichlorphenamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dichlorphenamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dichlorphenamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• diclofenac
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

diclofenac

1 interaction

Monitor/Modify Tx

salmeterol inhaled + diclofenac

monitor BP: combo may incr. risk of HTN (additive effects)

• diclofenac topical
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

salmeterol inhaled + diclofenac topical

monitor BP: combo may incr. risk of HTN (additive effects)

• dicyclomine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dicyclomine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dicyclomine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• diethylpropion
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

diethylpropion

1 interaction

Monitor/Modify Tx

salmeterol inhaled + diethylpropion

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• diflunisal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

diflunisal

1 interaction

Monitor/Modify Tx

salmeterol inhaled + diflunisal

monitor BP: combo may incr. risk of HTN (additive effects)

• digoxin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

digoxin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + digoxin

monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

• dihydroergotamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dihydroergotamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dihydroergotamine

monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

• diltiazem
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

diltiazem

1 interaction

Monitor/Modify Tx

salmeterol inhaled + diltiazem

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• dinutuximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dinutuximab

2 interactions

Monitor/Modify Tx

salmeterol inhaled + dinutuximab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + dinutuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• disopyramide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

disopyramide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + disopyramide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dobutamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dobutamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dobutamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• dofetilide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dofetilide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dofetilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

donepezil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dopamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dopamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dopamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• dordaviprone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dordaviprone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dordaviprone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxapram
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

doxapram

1 interaction

Monitor/Modify Tx

salmeterol inhaled + doxapram

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• doxazosin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

doxazosin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + doxazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• doxepin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

doxepin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + doxepin

monitor BP, HR during and x2wk after doxepin D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• dronedarone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dronedarone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + dronedarone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

droperidol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + droperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droxidopa
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

droxidopa

1 interaction

Monitor/Modify Tx

salmeterol inhaled + droxidopa

monitor BP, HR: combo may incr. risk of supine HTN, other cardiovascular adverse effects (additive effects)

• eletriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

eletriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + eletriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• emapalumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

emapalumab

2 interactions

Monitor/Modify Tx

salmeterol inhaled + emapalumab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + emapalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• enalapril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

enalapril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + enalapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• enalaprilat
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

enalaprilat

1 interaction

Monitor/Modify Tx

salmeterol inhaled + enalaprilat

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• encorafenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

encorafenib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + encorafenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ephedrine injection
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ephedrine injection

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ephedrine injection

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• ephedrine oral
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ephedrine oral

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ephedrine oral

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• epinephrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

epinephrine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + epinephrine

monitor potassium, ECG, BP, HR: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• epirubicin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

epirubicin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Caution Advised

fluticasone propionate + epirubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• eplerenone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

eplerenone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + eplerenone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• epoetin alfa
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

epoetin alfa

1 interaction

Monitor/Modify Tx

salmeterol inhaled + epoetin alfa

monitor BP: combo may incr. risk of HTN (additive effects)

• eptinezumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

eptinezumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + eptinezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• erenumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

erenumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + erenumab

monitor BP: combo may incr. risk of HTN (additive effects)

• ergotamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ergotamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ergotamine

monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

• eribulin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

eribulin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + eribulin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Caution Advised

fluticasone propionate + eribulin

caution advised: combo may incr. risk of serious infection (additive effects)

• erythromycin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

erythromycin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + erythromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• esketamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

esketamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + esketamine

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• estetrol (contraceptive)
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

estetrol (contraceptive)

1 interaction

Monitor/Modify Tx

salmeterol inhaled + estetrol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• estradiol (contraceptive)
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

salmeterol inhaled + estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• ethacrynic acid
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ethacrynic acid

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• ethanol (alcoholic beverage)
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ethanol (alcoholic beverage)

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ethanol (alcoholic beverage)

monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

• ethinyl estradiol (contraceptive)
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ethinyl estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• etodolac
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

etodolac

1 interaction

Monitor/Modify Tx

salmeterol inhaled + etodolac

monitor BP: combo may incr. risk of HTN (additive effects)

• etrasimod
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

etrasimod

2 interactions

Monitor/Modify Tx

salmeterol inhaled + etrasimod

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + etrasimod

caution advised during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• everolimus
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

everolimus

1 interaction

Monitor/Modify Tx

fluticasone propionate + everolimus

admin. PCP prophylaxis: combo may incr. risk of serious infection (additive effects)

• felodipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

felodipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + felodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenfluramine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fenfluramine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fenfluramine

monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

• fenoldopam
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fenoldopam

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fenoldopam

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenoprofen
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fenoprofen

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fenoprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• fingolimod
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fingolimod

2 interactions

Monitor/Modify Tx

salmeterol inhaled + fingolimod

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + fingolimod

caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• flecainide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

flecainide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + flecainide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fludrocortisone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fludrocortisone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + fludrocortisone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + fludrocortisone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• fluorouracil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fluorouracil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flurbiprofen
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

salmeterol inhaled + flurbiprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• foscarnet
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

foscarnet

1 interaction

Monitor/Modify Tx

salmeterol inhaled + foscarnet

monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• fosinopril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fosinopril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fosinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fostamatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fostamatinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fostamatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• fremanezumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fremanezumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + fremanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• frovatriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

frovatriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + frovatriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• fruquintinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fruquintinib

2 interactions

Monitor/Modify Tx

salmeterol inhaled + fruquintinib

monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

Caution Advised

fluticasone propionate + fruquintinib

caution advised: combo may incr. risk of serious infection (additive effects)

• galcanezumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

galcanezumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + galcanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• gilteritinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

gilteritinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + gilteritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

glasdegib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + glasdegib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glycopyrrolate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

glycopyrrolate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + glycopyrrolate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• goserelin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

goserelin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + goserelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• guanfacine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

guanfacine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + guanfacine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• haloperidol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

haloperidol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + haloperidol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

histrelin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + histrelin

consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hoodia
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hoodia

1 interaction

Monitor/Modify Tx

salmeterol inhaled + hoodia

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• hydralazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydralazine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + hydralazine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrochlorothiazide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + hydrochlorothiazide

monitor BP, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of hypokalemia, ECG changes (antagonistic effects; additive effects)

• hydrocortisone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydrocortisone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + hydrocortisone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + hydrocortisone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• hydroxocobalamin IV
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydroxocobalamin IV

1 interaction

Monitor/Modify Tx

salmeterol inhaled + hydroxocobalamin IV

monitor BP: combo may incr. risk of HTN (additive effects)

• hydroxyzine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + hydroxyzine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hyoscyamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + hyoscyamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ibrutinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ibrutinib

2 interactions

Monitor/Modify Tx

salmeterol inhaled + ibrutinib

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + ibrutinib

caution advised: combo may incr. risk of serious infection (additive effects)

• ibuprofen
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ibuprofen

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ibuprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• ibutilide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ibutilide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ibutilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• imipramine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

imipramine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + imipramine

monitor BP, HR during and x2wk after imipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• indapamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

indapamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + indapamide

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• indomethacin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

indomethacin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + indomethacin

monitor BP: combo may incr. risk of HTN (additive effects)

• inotuzumab ozogamicin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

inotuzumab ozogamicin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Caution Advised

fluticasone propionate + inotuzumab ozogamicin

caution advised: combo may incr. risk of serious infection (additive effects)

• insulin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

insulin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + insulin

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• irbesartan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

irbesartan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + irbesartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• isocarboxazid
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

isocarboxazid

1 interaction

Monitor/Modify Tx

salmeterol inhaled + isocarboxazid

monitor BP, HR during and x2wk after isocarboxazid D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• isoflurane
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

isoflurane

1 interaction

Monitor/Modify Tx

salmeterol inhaled + isoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoproterenol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

isoproterenol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + isoproterenol

monitor potassium, HR, BP: combo may incr. risk of hypokalemia, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• isradipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

isradipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + isradipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ivosidenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ivosidenib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ivosidenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ketamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ketamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ketamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other sympathomimetic adverse effects (additive effects)

• ketoprofen
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ketoprofen

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ketoprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• ketorolac
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ketorolac

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ketorolac

monitor BP: combo may incr. risk of HTN (additive effects)

• lanreotide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lanreotide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lanreotide

monitor BP: combo may incr. risk of HTN (additive effects)

• leflunomide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

leflunomide

2 interactions

Monitor/Modify Tx

salmeterol inhaled + leflunomide

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + leflunomide

caution advised: combo may incr. risk of serious infection (additive effects)

• lenalidomide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lenalidomide

2 interactions

Monitor/Modify Tx

salmeterol inhaled + lenalidomide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + lenalidomide

caution advised: combo may incr. risk of serious infection (additive effects)

• lenvatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lenvatinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lenvatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• leuprolide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

leuprolide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + leuprolide

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levalbuterol inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

salmeterol inhaled + levalbuterol inhaled

monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• levofloxacin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

levofloxacin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + levofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levomilnacipran
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

salmeterol inhaled + levomilnacipran

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• levothyroxine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

levothyroxine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + levothyroxine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• licorice
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

licorice

1 interaction

Monitor/Modify Tx

salmeterol inhaled + licorice

monitor BP, potassium w/ large amounts of licorice: combo may incr. risk of HTN, hypokalemia (additive effects)

• lifileucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lifileucel

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lifileucel

monitor HR: combo may incr. risk of tachycardia (additive effects)

• linezolid
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

linezolid

1 interaction

Monitor/Modify Tx

salmeterol inhaled + linezolid

monitor BP, HR during and x2wk after linezolid D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• liothyronine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

liothyronine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + liothyronine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• liraglutide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

liraglutide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + liraglutide

monitor HR: combo may incr. risk of tachycardia (additive effects)

• lisdexamfetamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lisdexamfetamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lisdexamfetamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• lisinopril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lisinopril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lisinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lofexidine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lofexidine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lorlatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lorlatinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lorlatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• losartan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

losartan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + losartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lumacaftor/ivacaftor
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lumacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

salmeterol inhaled + lumacaftor/ ivacaftor

monitor BP: combo may incr. risk of HTN (additive effects)

• luspatercept
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

luspatercept

1 interaction

Monitor/Modify Tx

salmeterol inhaled + luspatercept

monitor BP: combo may incr. risk of HTN (additive effects)

• macimorelin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

macimorelin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + macimorelin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• magnesium citrate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

magnesium citrate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + magnesium citrate

monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• magnesium salicylate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + magnesium salicylate

monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

• mannitol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mannitol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + mannitol

monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• meclofenamate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

meclofenamate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + meclofenamate

monitor BP: combo may incr. risk of HTN (additive effects)

• mefenamic acid
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

salmeterol inhaled + mefenamic acid

monitor BP: combo may incr. risk of HTN (additive effects)

• meloxicam
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

meloxicam

1 interaction

Monitor/Modify Tx

salmeterol inhaled + meloxicam

monitor BP: combo may incr. risk of HTN (additive effects)

• methacholine inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methacholine inhaled

2 interactions

Monitor/Modify Tx

salmeterol inhaled + methacholine inhaled

hold salmeterol at least 36h before methacholine test: combo may interfere with test results (antagonistic effects)

Caution Advised

fluticasone propionate + methacholine inhaled

caution advised: combo may interfere with test results (antagonistic effects)

• methadone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methadone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methadone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• methamphetamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methamphetamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methamphetamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• methazolamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methazolamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methazolamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• methoxy polyethylene glycol-epoetin beta
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methoxy polyethylene glycol-epoetin beta

monitor BP: combo may incr. risk of HTN (additive effects)

• methscopolamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methscopolamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methscopolamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• methyldopa
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methyldopa

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methyldopa

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• methylergonovine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methylergonovine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methylergonovine

monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

• methylphenidate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methylphenidate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methylphenidate

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• methylprednisolone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methylprednisolone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + methylprednisolone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + methylprednisolone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• methyltestosterone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methyltestosterone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + methyltestosterone

monitor BP: combo may incr. risk of HTN (additive effects)

• metoclopramide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

metoclopramide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + metoclopramide

monitor BP: combo may incr. risk of HTN (additive effects)

• metolazone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

metolazone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + metolazone

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• metyrapone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

metyrapone

1 interaction

Monitor/Modify Tx

fluticasone propionate + metyrapone

D/C fluticasone 5 half-lives before metyrapone test: combo may alter test results (antagonistic effects, exogenous corticosteroids may interfere with test)

• milnacipran
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

milnacipran

1 interaction

Monitor/Modify Tx

salmeterol inhaled + milnacipran

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• minoxidil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

minoxidil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + minoxidil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• mirabegron
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mirabegron

1 interaction

Monitor/Modify Tx

salmeterol inhaled + mirabegron

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• mitomycin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mitomycin

1 interaction

Monitor/Modify Tx

fluticasone propionate + mitomycin

caution advised; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of serious infection (additive effects)

• modafinil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

modafinil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + modafinil

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• moexipril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

moexipril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + moexipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• motixafortide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

motixafortide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + motixafortide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• moxifloxacin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + moxifloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nabumetone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nabumetone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nabumetone

monitor BP: combo may incr. risk of HTN (additive effects)

• naproxen
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

naproxen

1 interaction

Monitor/Modify Tx

salmeterol inhaled + naproxen

monitor BP: combo may incr. risk of HTN (additive effects)

• naratriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

naratriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + naratriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• naxitamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

naxitamab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + naxitamab

monitor BP: combo may incr. risk of HTN (additive effects)

• necitumumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

necitumumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + necitumumab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• nicardipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nicardipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nicardipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nifedipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nifedipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nifedipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nilotinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nilotinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nilotinib

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• nimodipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nimodipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nimodipine

monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

• niraparib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

niraparib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + niraparib

monitor BP: combo may incr. risk of HTN (additive effects)

• nisoldipine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nisoldipine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nisoldipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• norepinephrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

norepinephrine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + norepinephrine

monitor BP, HR: combo may incr. risk of severe HTN, other cardiovascular adverse effects (additive effects)

• nortriptyline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nortriptyline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + nortriptyline

monitor BP, HR during and x2wk after nortriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• obinutuzumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

obinutuzumab

2 interactions

Monitor/Modify Tx

salmeterol inhaled + obinutuzumab

monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

Caution Advised

fluticasone propionate + obinutuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• oliceridine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

oliceridine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + oliceridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olmesartan medoxomil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + olmesartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ondansetron
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ondansetron

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ondansetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• orphenadrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

orphenadrine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + orphenadrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• osilodrostat
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

osilodrostat

1 interaction

Monitor/Modify Tx

salmeterol inhaled + osilodrostat

monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

• osimertinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

osimertinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + osimertinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaprozin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

oxaprozin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + oxaprozin

monitor BP: combo may incr. risk of HTN (additive effects)

• oxymetazoline nasal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

oxymetazoline nasal

1 interaction

Monitor/Modify Tx

salmeterol inhaled + oxymetazoline nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• oxytocin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

oxytocin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + oxytocin

monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

• ozanimod
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ozanimod

2 interactions

Monitor/Modify Tx

salmeterol inhaled + ozanimod

monitor BP, HR during and x2wk after ozanimod D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

Caution Advised

fluticasone propionate + ozanimod

caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pacritinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pacritinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pacritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paliperidone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

paliperidone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + paliperidone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

palonosetron

1 interaction

Monitor/Modify Tx

salmeterol inhaled + palonosetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pamidronate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pamidronate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pamidronate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• panitumumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

panitumumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + panitumumab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• pasireotide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pasireotide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pazopanib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pazopanib

monitor BP: combo may incr. risk of HTN (additive effects)

• pentamidine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pentamidine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pentamidine

monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• perindopril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

perindopril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + perindopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• pexidartinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pexidartinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pexidartinib

monitor BP: combo may incr. risk of HTN (additive effects)

• phendimetrazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phendimetrazine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phendimetrazine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• phenoxybenzamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phenoxybenzamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phentermine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phentermine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phentermine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• phentolamine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phentolamine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phentolamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phenylephrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenylephrine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phenylephrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• phenylephrine injection
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenylephrine injection

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phenylephrine injection

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• phenylephrine nasal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenylephrine nasal

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phenylephrine nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenylephrine ophthalmic

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phenylephrine ophthalmic

monitor BP, HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN, tachycardia (additive effects)

• phenylephrine rectal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

phenylephrine rectal

1 interaction

Monitor/Modify Tx

salmeterol inhaled + phenylephrine rectal

monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

• piroxicam
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

piroxicam

1 interaction

Monitor/Modify Tx

salmeterol inhaled + piroxicam

monitor BP: combo may incr. risk of HTN (additive effects)

• polyethylene glycol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

polyethylene glycol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + polyethylene glycol

monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• polyethylene glycol/electrolytes
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

polyethylene glycol/ electrolytes

1 interaction

Monitor/Modify Tx

salmeterol inhaled + polyethylene glycol/ electrolytes

monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• ponatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ponatinib

2 interactions

Monitor/Modify Tx

salmeterol inhaled + ponatinib

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + ponatinib

caution advised: combo may incr. risk of serious infection (additive effects)

• ponesimod
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ponesimod

2 interactions

Monitor/Modify Tx

salmeterol inhaled + ponesimod

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + ponesimod

caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pralsetinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pralsetinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pralsetinib

monitor BP: combo may incr. risk of HTN (additive effects)

• prazosin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

prazosin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + prazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• prednisolone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

prednisolone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + prednisolone

monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

Caution Advised

fluticasone propionate + prednisolone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• prednisone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

prednisone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + prednisone

monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

Caution Advised

fluticasone propionate + prednisone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• procainamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

procainamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + procainamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

propafenone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + propafenone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• protriptyline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

protriptyline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + protriptyline

monitor BP, HR during and x2wk after protriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• pseudoephedrine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pseudoephedrine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + pseudoephedrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• quetiapine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

quetiapine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + quetiapine

monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

• quinapril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

quinapril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + quinapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• quinidine (antiarrhythmic)
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

salmeterol inhaled + quinidine (antiarrhythmic)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

salmeterol inhaled + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

quinine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + quinine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ramipril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ramipril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ramipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ramucirumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ramucirumab

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ramucirumab

monitor BP: combo may incr. risk of HTN (additive effects)

• rasagiline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rasagiline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + rasagiline

monitor BP, HR during and x2wk after rasagiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• regorafenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

regorafenib

2 interactions

Monitor/Modify Tx

salmeterol inhaled + regorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + regorafenib

caution advised: combo may incr. risk of serious infection (additive effects)

• revumenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

revumenib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rimegepant
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rimegepant

1 interaction

Monitor/Modify Tx

salmeterol inhaled + rimegepant

monitor BP: combo may incr. risk of HTN (additive effects)

• ripretinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ripretinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ripretinib

monitor BP: combo may incr. risk of HTN (additive effects)

• rizatriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rizatriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + rizatriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• romidepsin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

romidepsin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Caution Advised

fluticasone propionate + romidepsin

caution advised: combo may incr. risk of serious infection (additive effects)

• ropinirole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ropinirole

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ropinirole

monitor BP: combo may incr. risk of HTN (additive effects)

• rotigotine transdermal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

salmeterol inhaled + rotigotine transdermal

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• rucaparib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rucaparib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + rucaparib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sacituzumab govitecan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sacituzumab govitecan

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• safinamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

safinamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + safinamide

monitor BP, HR during and x2wk after safinamide D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• salsalate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

salsalate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + salsalate

monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

• selegiline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

selegiline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + selegiline

monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• selegiline transdermal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

selegiline transdermal

1 interaction

Monitor/Modify Tx

salmeterol inhaled + selegiline transdermal

monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• selinexor
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

selinexor

2 interactions

Monitor/Modify Tx

salmeterol inhaled + selinexor

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + selinexor

caution advised: combo may incr. risk of serious infection (additive effects)

• selpercatinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

selpercatinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + selpercatinib

monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

• sevoflurane
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sevoflurane

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sevoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• siponimod
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

siponimod

2 interactions

Monitor/Modify Tx

salmeterol inhaled + siponimod

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + siponimod

caution advised during and x3-4wk after siponimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• sirolimus albumin-bound
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sirolimus albumin-bound

2 interactions

Monitor/Modify Tx

salmeterol inhaled + sirolimus albumin-bound

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + sirolimus albumin-bound

caution advised: combo may incr. risk of serious infection (additive effects)

• sodium benzoate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sodium benzoate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sodium benzoate

monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

• sodium phenylacetate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sodium phenylacetate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sodium phenylacetate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• sodium phenylbutyrate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sodium phenylbutyrate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sodium phenylbutyrate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• sodium polystyrene sulfonate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sodium polystyrene sulfonate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sodium polystyrene sulfonate

monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• sodium thiosulfate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sodium thiosulfate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sodium thiosulfate

if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

• solriamfetol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

solriamfetol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + solriamfetol

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• sorafenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sorafenib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

• spironolactone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

spironolactone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + spironolactone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• sulfate bowel prep
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sulfate bowel prep

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sulfate bowel prep

monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• sulindac
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sulindac

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sulindac

monitor BP: combo may incr. risk of HTN (additive effects)

• sumatriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sumatriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sumatriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• sunitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sunitinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + sunitinib

monitor BP: combo may incr. risk of HTN (additive effects)

• tacrolimus
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tacrolimus

2 interactions

Monitor/Modify Tx

salmeterol inhaled + tacrolimus

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + tacrolimus

caution advised: combo may incr. risk of serious infection (additive effects)

• tafasitamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tafasitamab

2 interactions

Monitor/Modify Tx

salmeterol inhaled + tafasitamab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

fluticasone propionate + tafasitamab

caution advised: combo may incr. risk of serious infection (additive effects)

• tagraxofusp
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

salmeterol inhaled + tagraxofusp

monitor BP: combo may incr. risk of HTN (additive effects)

• taletrectinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

taletrectinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + taletrectinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telavancin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

telavancin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telmisartan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

telmisartan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + telmisartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terazosin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

terazosin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + terazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terbutaline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

terbutaline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + terbutaline

monitor potassium, BP, HR: combo may incr. risk of hypokalemia, ECG changes, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

• teriflunomide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

teriflunomide

2 interactions

Monitor/Modify Tx

salmeterol inhaled + teriflunomide

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + teriflunomide

caution advised: combo may incr. risk of serious infection (additive effects)

• testosterone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

testosterone

1 interaction

Monitor/Modify Tx

salmeterol inhaled + testosterone

monitor BP: combo may incr. risk of HTN (additive effects)

• tetrabenazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + tetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• theophylline
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

theophylline

1 interaction

Monitor/Modify Tx

salmeterol inhaled + theophylline

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• thyroid
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

thyroid

1 interaction

Monitor/Modify Tx

salmeterol inhaled + thyroid

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• tivozanib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tivozanib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + tivozanib

monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

• tolmetin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tolmetin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + tolmetin

monitor BP: combo may incr. risk of HTN (additive effects)

• topiramate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

topiramate

1 interaction

Monitor/Modify Tx

salmeterol inhaled + topiramate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• torsemide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

torsemide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + torsemide

monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

• tramadol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tramadol

1 interaction

Monitor/Modify Tx

salmeterol inhaled + tramadol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trametinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

trametinib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + trametinib

monitor BP: combo may incr. risk of HTN (additive effects)

• trandolapril
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

trandolapril

1 interaction

Monitor/Modify Tx

salmeterol inhaled + trandolapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• tranylcypromine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tranylcypromine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + tranylcypromine

monitor BP, HR during and x2wk after tranylcypromine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

• triamcinolone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

triamcinolone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + triamcinolone

monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

Caution Advised

fluticasone propionate + triamcinolone

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• triamterene
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

triamterene

1 interaction

Monitor/Modify Tx

salmeterol inhaled + triamterene

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• triclabendazole
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

triclabendazole

1 interaction

Monitor/Modify Tx

salmeterol inhaled + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

trifluridine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimipramine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

trimipramine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + trimipramine

monitor BP, HR during and x2wk after trimipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• triptorelin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

triptorelin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + triptorelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• trospium
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

trospium

1 interaction

Monitor/Modify Tx

salmeterol inhaled + trospium

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ubrogepant
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ubrogepant

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ubrogepant

monitor BP: combo may incr. risk of HTN (additive effects)

• vadadustat
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vadadustat

1 interaction

Monitor/Modify Tx

salmeterol inhaled + vadadustat

monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

• valsartan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

valsartan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + valsartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• vamorolone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vamorolone

2 interactions

Monitor/Modify Tx

salmeterol inhaled + vamorolone

monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

Caution Advised

fluticasone propionate + vamorolone

caution advised: combo may incr. risk of serious infection (additive effects)

• vasopressin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vasopressin

1 interaction

Monitor/Modify Tx

salmeterol inhaled + vasopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• vemurafenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vemurafenib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + vemurafenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• venlafaxine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

venlafaxine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + venlafaxine

monitor BP: combo may incr. risk of HTN (additive effects)

• verapamil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

verapamil

1 interaction

Monitor/Modify Tx

salmeterol inhaled + verapamil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• viloxazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

viloxazine

1 interaction

Monitor/Modify Tx

salmeterol inhaled + viloxazine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• voclosporin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

voclosporin

2 interactions

Monitor/Modify Tx

salmeterol inhaled + voclosporin

monitor BP: combo may incr. risk of HTN (additive effects)

Caution Advised

fluticasone propionate + voclosporin

caution advised: combo may incr. risk of serious infection (additive effects)

• yohimbe
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

yohimbe

1 interaction

Monitor/Modify Tx

salmeterol inhaled + yohimbe

monitor BP, HR during and x2wk after yohimbe D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• zavegepant
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

zavegepant

1 interaction

Monitor/Modify Tx

salmeterol inhaled + zavegepant

monitor BP: combo may incr. risk of HTN (additive effects)

• ziftomenib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ziftomenib

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ziftomenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziv-aflibercept
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

salmeterol inhaled + ziv-aflibercept

monitor BP: combo may incr. risk of HTN (additive effects)

• zolmitriptan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

salmeterol inhaled + zolmitriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• zonisamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

zonisamide

1 interaction

Monitor/Modify Tx

salmeterol inhaled + zonisamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

• abatacept
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

abatacept

1 interaction

Caution Advised

fluticasone propionate + abatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• abemaciclib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

abemaciclib

1 interaction

Caution Advised

fluticasone propionate + abemaciclib

caution advised: combo may incr. risk of serious infection (additive effects)

• abrocitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

abrocitinib

1 interaction

Caution Advised

fluticasone propionate + abrocitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• acalabrutinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

acalabrutinib

1 interaction

Caution Advised

fluticasone propionate + acalabrutinib

caution advised: combo may incr. risk of serious infection (additive effects)

• adalimumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

adalimumab

1 interaction

Caution Advised

fluticasone propionate + adalimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• afamitresgene autoleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

afamitresgene autoleucel

1 interaction

Caution Advised

fluticasone propionate + afamitresgene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• aldesleukin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

aldesleukin

1 interaction

Caution Advised

fluticasone propionate + aldesleukin

caution advised: combo may incr. risk of serious infection (additive effects)

• alemtuzumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

alemtuzumab

1 interaction

Caution Advised

fluticasone propionate + alemtuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• anakinra
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

anakinra

1 interaction

Caution Advised

fluticasone propionate + anakinra

caution advised: combo may incr. risk of serious infection (additive effects)

• anifrolumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

anifrolumab

1 interaction

Caution Advised

fluticasone propionate + anifrolumab

caution advised: combo may incr. risk of serious infection (additive effects)

• anti-thymocyte globulin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

anti-thymocyte globulin

1 interaction

Caution Advised

fluticasone propionate + anti-thymocyte globulin

caution advised: combo may incr. risk of serious infection (additive effects)

• atidarsagene autotemcel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

atidarsagene autotemcel

1 interaction

Caution Advised

fluticasone propionate + atidarsagene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• avacopan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

avacopan

1 interaction

Caution Advised

fluticasone propionate + avacopan

caution advised: combo may incr. risk of serious infection (additive effects)

• axicabtagene ciloleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

axicabtagene ciloleucel

1 interaction

Caution Advised

fluticasone propionate + axicabtagene ciloleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• azacitidine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

azacitidine

1 interaction

Caution Advised

fluticasone propionate + azacitidine

caution advised: combo may incr. risk of serious infection (additive effects)

• azathioprine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

azathioprine

1 interaction

Caution Advised

fluticasone propionate + azathioprine

caution advised: combo may incr. risk of serious infection (additive effects)

• baricitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

baricitinib

1 interaction

Caution Advised

fluticasone propionate + baricitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• basiliximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

basiliximab

1 interaction

Caution Advised

fluticasone propionate + basiliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

beclomethasone inhaled

1 interaction

Caution Advised

fluticasone propionate + beclomethasone inhaled

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• beclomethasone nasal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

beclomethasone nasal

1 interaction

Caution Advised

fluticasone propionate + beclomethasone nasal

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• belatacept
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

belatacept

1 interaction

Caution Advised

fluticasone propionate + belatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• belimumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

belimumab

1 interaction

Caution Advised

fluticasone propionate + belimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• belinostat
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

belinostat

1 interaction

Caution Advised

fluticasone propionate + belinostat

caution advised: combo may incr. risk of serious infection (additive effects)

• bendamustine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bendamustine

1 interaction

Caution Advised

fluticasone propionate + bendamustine

caution advised: combo may incr. risk of serious infection (additive effects)

• bimekizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bimekizumab

1 interaction

Caution Advised

fluticasone propionate + bimekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• blinatumomab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

blinatumomab

1 interaction

Caution Advised

fluticasone propionate + blinatumomab

caution advised: combo may incr. risk of serious infection (additive effects)

• bortezomib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

bortezomib

1 interaction

Caution Advised

fluticasone propionate + bortezomib

caution advised: combo may incr. risk of serious infection (additive effects)

• brentuximab vedotin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

brentuximab vedotin

1 interaction

Caution Advised

fluticasone propionate + brentuximab vedotin

caution advised: combo may incr. risk of serious infection (additive effects)

• brexucabtagene autoleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

brexucabtagene autoleucel

1 interaction

Caution Advised

fluticasone propionate + brexucabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• brodalumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

brodalumab

1 interaction

Caution Advised

fluticasone propionate + brodalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

budesonide inhaled

1 interaction

Caution Advised

fluticasone propionate + budesonide inhaled

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• budesonide nasal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

budesonide nasal

1 interaction

Caution Advised

fluticasone propionate + budesonide nasal

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• budesonide rectal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

budesonide rectal

1 interaction

Caution Advised

fluticasone propionate + budesonide rectal

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• busulfan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

busulfan

1 interaction

Caution Advised

fluticasone propionate + busulfan

caution advised: combo may incr. risk of serious infection (additive effects)

• cabazitaxel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cabazitaxel

1 interaction

Caution Advised

fluticasone propionate + cabazitaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• canakinumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

canakinumab

1 interaction

Caution Advised

fluticasone propionate + canakinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• carboplatin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

carboplatin

1 interaction

Caution Advised

fluticasone propionate + carboplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• carmustine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

carmustine

1 interaction

Caution Advised

fluticasone propionate + carmustine

caution advised: combo may incr. risk of serious infection (additive effects)

• certolizumab pegol
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

certolizumab pegol

1 interaction

Caution Advised

fluticasone propionate + certolizumab pegol

caution advised: combo may incr. risk of serious infection (additive effects)

• chlorambucil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

chlorambucil

1 interaction

Caution Advised

fluticasone propionate + chlorambucil

caution advised: combo may incr. risk of serious infection (additive effects)

• ciltacabtagene autoleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ciltacabtagene autoleucel

1 interaction

Caution Advised

fluticasone propionate + ciltacabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• cladribine injection
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cladribine injection

1 interaction

Caution Advised

fluticasone propionate + cladribine injection

caution advised: combo may incr. risk of serious infection (additive effects)

• clobetasol ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clobetasol ophthalmic

1 interaction

Caution Advised

fluticasone propionate + clobetasol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• clofarabine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

clofarabine

1 interaction

Caution Advised

fluticasone propionate + clofarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• crovalimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

crovalimab

1 interaction

Caution Advised

fluticasone propionate + crovalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• cyclophosphamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cyclophosphamide

1 interaction

Caution Advised

fluticasone propionate + cyclophosphamide

caution advised: combo may incr. risk of serious infection (additive effects)

• cytarabine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

cytarabine

1 interaction

Caution Advised

fluticasone propionate + cytarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• dactinomycin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dactinomycin

1 interaction

Caution Advised

fluticasone propionate + dactinomycin

caution advised: combo may incr. risk of serious infection (additive effects)

• danicopan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

danicopan

1 interaction

Caution Advised

fluticasone propionate + danicopan

caution advised: combo may incr. risk of serious infection (additive effects)

• daratumumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

daratumumab

1 interaction

Caution Advised

fluticasone propionate + daratumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• daunorubicin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

daunorubicin

1 interaction

Caution Advised

fluticasone propionate + daunorubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• delgocitinib topical
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

delgocitinib topical

1 interaction

Caution Advised

fluticasone propionate + delgocitinib topical

caution advised: combo may incr. risk of serious infection (additive effects)

• deucravacitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

deucravacitinib

1 interaction

Caution Advised

fluticasone propionate + deucravacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• deuruxolitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

deuruxolitinib

1 interaction

Caution Advised

fluticasone propionate + deuruxolitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• dexamethasone ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dexamethasone ophthalmic

1 interaction

Caution Advised

fluticasone propionate + dexamethasone ophthalmic

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• difluprednate ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

difluprednate ophthalmic

1 interaction

Caution Advised

fluticasone propionate + difluprednate ophthalmic

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• dimethyl fumarate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dimethyl fumarate

1 interaction

Caution Advised

fluticasone propionate + dimethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• diroximel fumarate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

diroximel fumarate

1 interaction

Caution Advised

fluticasone propionate + diroximel fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• docetaxel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

docetaxel

1 interaction

Caution Advised

fluticasone propionate + docetaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• doxorubicin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

doxorubicin

1 interaction

Caution Advised

fluticasone propionate + doxorubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• dupilumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

dupilumab

1 interaction

Caution Advised

fluticasone propionate + dupilumab

caution advised: combo may incr. risk of serious infection (additive effects)

• duvelisib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

duvelisib

1 interaction

Caution Advised

fluticasone propionate + duvelisib

caution advised: combo may incr. risk of serious infection (additive effects)

• eculizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

eculizumab

1 interaction

Caution Advised

fluticasone propionate + eculizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• efgartigimod alfa
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

efgartigimod alfa

1 interaction

Caution Advised

fluticasone propionate + efgartigimod alfa

caution advised: combo may incr. risk of serious infection (additive effects)

• elivaldogene autotemcel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

elivaldogene autotemcel

1 interaction

Caution Advised

fluticasone propionate + elivaldogene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• elotuzumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

elotuzumab

1 interaction

Caution Advised

fluticasone propionate + elotuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• elranatamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

elranatamab

1 interaction

Caution Advised

fluticasone propionate + elranatamab

caution advised: combo may incr. risk of serious infection (additive effects)

• epcoritamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

epcoritamab

1 interaction

Caution Advised

fluticasone propionate + epcoritamab

caution advised: combo may incr. risk of serious infection (additive effects)

• etanercept
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

etanercept

1 interaction

Caution Advised

fluticasone propionate + etanercept

caution advised: combo may incr. risk of serious infection (additive effects)

• etoposide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

etoposide

1 interaction

Caution Advised

fluticasone propionate + etoposide

caution advised: combo may incr. risk of serious infection (additive effects)

• etuvetidigene autotemcel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

etuvetidigene autotemcel

1 interaction

Caution Advised

fluticasone propionate + etuvetidigene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• floxuridine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

floxuridine

1 interaction

Caution Advised

fluticasone propionate + floxuridine

caution advised: combo may incr. risk of serious infection (additive effects)

• fludarabine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fludarabine

1 interaction

Caution Advised

fluticasone propionate + fludarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• flunisolide nasal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

flunisolide nasal

1 interaction

Caution Advised

fluticasone propionate + flunisolide nasal

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• fluocinolone intravitreal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fluocinolone intravitreal

1 interaction

Caution Advised

fluticasone propionate + fluocinolone intravitreal

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• fluorometholone ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fluorometholone ophthalmic

1 interaction

Caution Advised

fluticasone propionate + fluorometholone ophthalmic

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• fluticasone furoate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

fluticasone furoate

1 interaction

Caution Advised

fluticasone propionate + fluticasone furoate

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• gemtuzumab ozogamicin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

gemtuzumab ozogamicin

1 interaction

Caution Advised

fluticasone propionate + gemtuzumab ozogamicin

caution advised: combo may incr. risk of serious infection (additive effects)

• glofitamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

glofitamab

1 interaction

Caution Advised

fluticasone propionate + glofitamab

caution advised: combo may incr. risk of serious infection (additive effects)

• golimumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

golimumab

1 interaction

Caution Advised

fluticasone propionate + golimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• guselkumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

guselkumab

1 interaction

Caution Advised

fluticasone propionate + guselkumab

caution advised: combo may incr. risk of serious infection (additive effects)

• hydrocortisone ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydrocortisone ophthalmic

1 interaction

Caution Advised

fluticasone propionate + hydrocortisone ophthalmic

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• hydroxyurea
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

hydroxyurea

1 interaction

Caution Advised

fluticasone propionate + hydroxyurea

caution advised: combo may incr. risk of serious infection (additive effects)

• ibritumomab tiuxetan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ibritumomab tiuxetan

1 interaction

Caution Advised

fluticasone propionate + ibritumomab tiuxetan

caution advised: combo may incr. risk of serious infection (additive effects)

• icotrokinra
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

icotrokinra

1 interaction

Caution Advised

fluticasone propionate + icotrokinra

caution advised: combo may incr. risk of serious infection (additive effects)

• idarubicin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

idarubicin

1 interaction

Caution Advised

fluticasone propionate + idarubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• idecabtagene vicleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

idecabtagene vicleucel

1 interaction

Caution Advised

fluticasone propionate + idecabtagene vicleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• ifosfamide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ifosfamide

1 interaction

Caution Advised

fluticasone propionate + ifosfamide

caution advised: combo may incr. risk of serious infection (additive effects)

• inebilizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

inebilizumab

1 interaction

Caution Advised

fluticasone propionate + inebilizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• infliximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

infliximab

1 interaction

Caution Advised

fluticasone propionate + infliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• iptacopan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

iptacopan

1 interaction

Caution Advised

fluticasone propionate + iptacopan

caution advised: combo may incr. risk of serious infection (additive effects)

• irinotecan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

irinotecan

1 interaction

Caution Advised

fluticasone propionate + irinotecan

caution advised: combo may incr. risk of serious infection (additive effects)

• isatuximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

isatuximab

1 interaction

Caution Advised

fluticasone propionate + isatuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• ixabepilone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ixabepilone

1 interaction

Caution Advised

fluticasone propionate + ixabepilone

caution advised: combo may incr. risk of serious infection (additive effects)

• ixekizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ixekizumab

1 interaction

Caution Advised

fluticasone propionate + ixekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• lebrikizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lebrikizumab

1 interaction

Caution Advised

fluticasone propionate + lebrikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• linvoseltamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

linvoseltamab

1 interaction

Caution Advised

fluticasone propionate + linvoseltamab

caution advised: combo may incr. risk of serious infection (additive effects)

• lisocabtagene maraleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lisocabtagene maraleucel

1 interaction

Caution Advised

fluticasone propionate + lisocabtagene maraleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• lomustine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lomustine

1 interaction

Caution Advised

fluticasone propionate + lomustine

caution advised: combo may incr. risk of serious infection (additive effects)

• loncastuximab tesirine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

loncastuximab tesirine

1 interaction

Caution Advised

fluticasone propionate + loncastuximab tesirine

caution advised: combo may incr. risk of serious infection (additive effects)

• loteprednol ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

loteprednol ophthalmic

1 interaction

Caution Advised

fluticasone propionate + loteprednol ophthalmic

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• lymphocyte immune globulin, anti-thymocyte globulin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Caution Advised

fluticasone propionate + lymphocyte immune globulin, anti-thymocyte globulin

caution advised: combo may incr. risk of serious infection (additive effects)

• melphalan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

melphalan

1 interaction

Caution Advised

fluticasone propionate + melphalan

caution advised: combo may incr. risk of serious infection (additive effects)

• mercaptopurine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mercaptopurine

1 interaction

Caution Advised

fluticasone propionate + mercaptopurine

caution advised: combo may incr. risk of serious infection (additive effects)

• methotrexate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

methotrexate

1 interaction

Caution Advised

fluticasone propionate + methotrexate

caution advised: combo may incr. risk of serious infection (additive effects)

• mirikizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mirikizumab

1 interaction

Caution Advised

fluticasone propionate + mirikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mitoxantrone
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mitoxantrone

1 interaction

Caution Advised

fluticasone propionate + mitoxantrone

caution advised: combo may incr. risk of serious infection (additive effects)

• mogamulizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mogamulizumab

1 interaction

Caution Advised

fluticasone propionate + mogamulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• momelotinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

momelotinib

1 interaction

Caution Advised

fluticasone propionate + momelotinib

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone implant
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mometasone implant

1 interaction

Caution Advised

fluticasone propionate + mometasone implant

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• mometasone inhaled
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mometasone inhaled

1 interaction

Caution Advised

fluticasone propionate + mometasone inhaled

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• mometasone nasal
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mometasone nasal

1 interaction

Caution Advised

fluticasone propionate + mometasone nasal

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• monomethyl fumarate
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

monomethyl fumarate

1 interaction

Caution Advised

fluticasone propionate + monomethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• mosunetuzumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mosunetuzumab

1 interaction

Caution Advised

fluticasone propionate + mosunetuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mycophenolate mofetil
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mycophenolate mofetil

1 interaction

Caution Advised

fluticasone propionate + mycophenolate mofetil

caution advised: combo may incr. risk of serious infection (additive effects)

• mycophenolic acid
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

mycophenolic acid

1 interaction

Caution Advised

fluticasone propionate + mycophenolic acid

caution advised: combo may incr. risk of serious infection (additive effects)

• narsoplimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

narsoplimab

1 interaction

Caution Advised

fluticasone propionate + narsoplimab

caution advised: combo may incr. risk of serious infection (additive effects)

• nelarabine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nelarabine

1 interaction

Caution Advised

fluticasone propionate + nelarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• nipocalimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

nipocalimab

1 interaction

Caution Advised

fluticasone propionate + nipocalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• obecabtagene autoleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

obecabtagene autoleucel

1 interaction

Caution Advised

fluticasone propionate + obecabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• ocrelizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ocrelizumab

1 interaction

Caution Advised

fluticasone propionate + ocrelizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ofatumumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ofatumumab

1 interaction

Caution Advised

fluticasone propionate + ofatumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• oxaliplatin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

oxaliplatin

1 interaction

Caution Advised

fluticasone propionate + oxaliplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• paclitaxel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

paclitaxel

1 interaction

Caution Advised

fluticasone propionate + paclitaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• pegcetacoplan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pegcetacoplan

1 interaction

Caution Advised

fluticasone propionate + pegcetacoplan

caution advised: combo may incr. risk of serious infection (additive effects)

• pentostatin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pentostatin

1 interaction

Caution Advised

fluticasone propionate + pentostatin

caution advised: combo may incr. risk of serious infection (additive effects)

• pirtobrutinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pirtobrutinib

1 interaction

Caution Advised

fluticasone propionate + pirtobrutinib

caution advised: combo may incr. risk of serious infection (additive effects)

• polatuzumab vedotin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

polatuzumab vedotin

1 interaction

Caution Advised

fluticasone propionate + polatuzumab vedotin

caution advised: combo may incr. risk of serious infection (additive effects)

• pomalidomide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pomalidomide

1 interaction

Caution Advised

fluticasone propionate + pomalidomide

caution advised: combo may incr. risk of serious infection (additive effects)

• pozelimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

pozelimab

1 interaction

Caution Advised

fluticasone propionate + pozelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone ophthalmic
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

prednisolone ophthalmic

1 interaction

Caution Advised

fluticasone propionate + prednisolone ophthalmic

caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

• ravulizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ravulizumab

1 interaction

Caution Advised

fluticasone propionate + ravulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• rilonacept
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rilonacept

1 interaction

Caution Advised

fluticasone propionate + rilonacept

caution advised: combo may incr. risk of serious infection (additive effects)

• rilzabrutinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rilzabrutinib

1 interaction

Caution Advised

fluticasone propionate + rilzabrutinib

caution advised: combo may incr. risk of serious infection (additive effects)

• risankizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

risankizumab

1 interaction

Caution Advised

fluticasone propionate + risankizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ritlecitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ritlecitinib

1 interaction

Caution Advised

fluticasone propionate + ritlecitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• rituximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rituximab

1 interaction

Caution Advised

fluticasone propionate + rituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• ropeginterferon alfa-2b
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ropeginterferon alfa-2b

1 interaction

Caution Advised

fluticasone propionate + ropeginterferon alfa-2b

caution advised: combo may incr. risk of serious infection (additive effects)

• rozanolixizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

rozanolixizumab

1 interaction

Caution Advised

fluticasone propionate + rozanolixizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ruxolitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ruxolitinib

1 interaction

Caution Advised

fluticasone propionate + ruxolitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• ruxolitinib topical
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ruxolitinib topical

1 interaction

Caution Advised

fluticasone propionate + ruxolitinib topical

caution advised: combo may incr. risk of serious infection (additive effects)

• sarilumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sarilumab

1 interaction

Caution Advised

fluticasone propionate + sarilumab

caution advised: combo may incr. risk of serious infection (additive effects)

• satralizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

satralizumab

1 interaction

Caution Advised

fluticasone propionate + satralizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• secukinumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

secukinumab

1 interaction

Caution Advised

fluticasone propionate + secukinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• sibeprenlimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sibeprenlimab

1 interaction

Caution Advised

fluticasone propionate + sibeprenlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• siltuximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

siltuximab

1 interaction

Caution Advised

fluticasone propionate + siltuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• sirolimus
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sirolimus

1 interaction

Caution Advised

fluticasone propionate + sirolimus

caution advised: combo may incr. risk of serious infection (additive effects)

• spesolimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

spesolimab

1 interaction

Caution Advised

fluticasone propionate + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

• sulfasalazine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sulfasalazine

1 interaction

Caution Advised

fluticasone propionate + sulfasalazine

caution advised: combo may incr. risk of serious infection (additive effects)

• sutimlimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

sutimlimab

1 interaction

Caution Advised

fluticasone propionate + sutimlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• talquetamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

talquetamab

1 interaction

Caution Advised

fluticasone propionate + talquetamab

caution advised: combo may incr. risk of serious infection (additive effects)

• tarlatamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tarlatamab

1 interaction

Caution Advised

fluticasone propionate + tarlatamab

caution advised: combo may incr. risk of serious infection (additive effects)

• teclistamab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

teclistamab

1 interaction

Caution Advised

fluticasone propionate + teclistamab

caution advised: combo may incr. risk of serious infection (additive effects)

• temozolomide
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

temozolomide

1 interaction

Caution Advised

fluticasone propionate + temozolomide

caution advised: combo may incr. risk of serious infection (additive effects)

• temsirolimus
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

temsirolimus

1 interaction

Caution Advised

fluticasone propionate + temsirolimus

caution advised: combo may incr. risk of serious infection (additive effects)

• teplizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

teplizumab

1 interaction

Caution Advised

fluticasone propionate + teplizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• thioguanine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

thioguanine

1 interaction

Caution Advised

fluticasone propionate + thioguanine

caution advised: combo may incr. risk of serious infection (additive effects)

• thiotepa
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

thiotepa

1 interaction

Caution Advised

fluticasone propionate + thiotepa

caution advised: combo may incr. risk of serious infection (additive effects)

• tildrakizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tildrakizumab

1 interaction

Caution Advised

fluticasone propionate + tildrakizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• tisagenlecleucel
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tisagenlecleucel

1 interaction

Caution Advised

fluticasone propionate + tisagenlecleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• tocilizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tocilizumab

1 interaction

Caution Advised

fluticasone propionate + tocilizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• tofacitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tofacitinib

1 interaction

Caution Advised

fluticasone propionate + tofacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• topotecan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

topotecan

1 interaction

Caution Advised

fluticasone propionate + topotecan

caution advised: combo may incr. risk of serious infection (additive effects)

• trabectedin
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

trabectedin

1 interaction

Caution Advised

fluticasone propionate + trabectedin

caution advised: combo may incr. risk of serious infection (additive effects)

• tralokinumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

tralokinumab

1 interaction

Caution Advised

fluticasone propionate + tralokinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ublituximab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ublituximab

1 interaction

Caution Advised

fluticasone propionate + ublituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• upadacitinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

upadacitinib

1 interaction

Caution Advised

fluticasone propionate + upadacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• ustekinumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

ustekinumab

1 interaction

Caution Advised

fluticasone propionate + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• vedolizumab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vedolizumab

1 interaction

Caution Advised

fluticasone propionate + vedolizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• venetoclax
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

venetoclax

1 interaction

Caution Advised

fluticasone propionate + venetoclax

caution advised: combo may incr. risk of serious infection (additive effects)

• vilobelimab
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vilobelimab

1 interaction

Caution Advised

fluticasone propionate + vilobelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• vinblastine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vinblastine

1 interaction

Caution Advised

fluticasone propionate + vinblastine

caution advised: combo may incr. risk of serious infection (additive effects)

• vincristine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vincristine

1 interaction

Caution Advised

fluticasone propionate + vincristine

caution advised: combo may incr. risk of serious infection (additive effects)

• vinorelbine
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

vinorelbine

1 interaction

Caution Advised

fluticasone propionate + vinorelbine

caution advised: combo may incr. risk of serious infection (additive effects)

• zanubrutinib
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

zanubrutinib

1 interaction

Caution Advised

fluticasone propionate + zanubrutinib

caution advised: combo may incr. risk of serious infection (additive effects)

• zilucoplan
Wixela Inhub (fluticasone propionate/ salmeterol inhaled)

+

zilucoplan

1 interaction

Caution Advised

fluticasone propionate + zilucoplan

caution advised: combo may incr. risk of serious infection (additive effects)